Interview 17 Apr 2019 What Does the Future Hold for European Biotech? Insights from Evotec’s CEO As the CEO of Evotec, one of Europe’s largest biotech companies, Werner Lanthaler is in a unique position to look into the future of the biotech industry. At Labiotech Refresh in Vienna, Lanthaler shared his views on where the industry is headed — and how to stay ahead of the game. The last decade has […] April 17, 2019 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2019 UK Biotech Uses Genetic Engineering to Control Crop Munching Caterpillars Moth caterpillars attacking crops are the latest target of the UK company Oxitec, which uses genetic engineering to suppress the populations of crop pests and disease-carrying mosquitoes. The caterpillars of the soybean looper moth Chrysodeixis includens eat crops such as soybean, tomato and cotton across North and South America, causing problems for farmers. The caterpillars […] April 17, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 16 Apr 2019 Researchers in Israel 3D Print a Personalized Heart from Donor’s Tissue A group of scientists in Israel is the first to 3D print a vascularized heart using reprogrammed cells and biological material from a donor. The technology could one day provide printed hearts for transplants with low risks of rejection by a patient’s immune system. Organ bioprinting is a technique similar to 3D printing where you […] April 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2019 Male-Pattern Baldness Could See First New Treatment in over 10 Years A skin cream developed by the Italian company Cassiopea has reduced male-pattern baldness for up to 12 months in a phase II trial. Androgenetic alopecia, commonly known as male-pattern baldness in men, is a very common condition where excess male hormones (androgens) in hair follicles stop hair growing on the scalp. There are only two […] April 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 16 Apr 2019 How to Outsource Your Content Creation Process to a Life Science Writer For many people, the mere thought of having to write a content piece comprising more than 200 words is daunting. In the life sciences, as in other industries, writing requires a specific skill set and uses time and energy which are often needed for other important tasks. In these situations, it can be helpful to […] April 16, 2019 - 9 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 15 Apr 2019 First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […] April 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Apr 2019 The Best Universities to Study Biotechnology in Europe Choosing the right university and program to study biotechnology can seem an insurmountable task, especially given the growing number of universities that offer courses in this booming field of study. We did some digging around to find a range of biotechnology programs with different specializations in some of the best universities in Europe. Each country […] April 15, 2019 - 14 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 12 Apr 2019 This Biotech Writes Long DNA Molecules From Scratch Writing long stretches of DNA is difficult and expensive. The Austrian biotech Ribbon Biolabs is combining automation with enzymes to make the process easier, with the prospect of improving synthetic biology applications. Mission: To synthesize DNA molecules with a length of up to 10,000 base pairs (the building blocks of DNA). This target is five […] April 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Apr 2019 Scientists Develop Treatment to Combat Antibiotic Resistance in Meningitis Researchers based in Sweden and Denmark are developing a meningitis treatment that could overcome antibiotic resistance by targeting white blood cells called neutrophils. Antibiotic resistance has become a pressing issue, as many easily treatable infections become harder to fight with traditional antibiotics. Bacterial meningitis is particularly concerning, as its already considerable mortality rate of 10-30% […] April 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2019 Swiss Multi-Cancer Diagnostic Test Approved in Europe A cancer test developed by the Swiss company SOPHiA GENETICS has been approved for diagnosing multiple types of solid tumors by looking at genetic variations in 42 genes. SOPHiA GENETICS works in data-driven medicine, using huge amounts of genomic data to diagnose and personalize treatments to a patient. This new technology is being adopted by […] April 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2019 Needle-Free Vaccine for Bubonic Plague to be Developed in the UK The UK biotech Enesi Pharma has joined forces with researchers from the University of Oxford to develop a vaccine for the bubonic plague that is simple to use and doesn’t require needles. Caused by the bacteria Yersinia pestis, the bubonic plague is infamous for having killed over 50 million Europeans in the Middle Ages. While […] April 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type 2 diabetes in a phase III trial in Japan. Poxel’s lead candidate drug imeglimin has taken a step closer to entering the huge market for diabetes type 2 treatments. In a phase III trial in […] April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email